The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

This paper, by Dr. Eugenia Xu and colleagues from the Sackler Foundation and Robert Wood Johnson Medical School and scientists from Constellation Pharmaceuticals, is now available in the open-access journal Cell Death and Disease.

View full paper here